Experts share their key takeaways from AUA 2024
In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.
In this video, Matthew Nielsen, MD, MS, FACS; Jay Simhan, MD, FACS; Sarah P. Psutka, MD, MSc; and Joshua Meeks, MD, PhD discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting, which took place from May 3-6 in San Antonio, Texas.
Nielsen is the chair of urology and the John Sloan Rhodes and John Flint Rhodes Distinguished professor of urology at the University of North Carolina in Chapel Hill.
Simhan is the vice chair of the department of urology, a professor of urology, the director of reconstruction and prosthetics, and the fellowship director for reconstructive and prosthetic urology fellowship program at Fox Chase Cancer Center/Temple Health in Philadelphia, PA.
Psutka is an associate professor of urology and the associate director of urologic oncology at the University of Washington in Seattle.
Meeks is the Edward M. Schaeffer, MD, PhD, professor of urology and an associate professor of urology and biochemistry and molecular genetics at Northwestern University School of Medicine in Chicago, Illinois.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
